UOC
ACRS icon

UBS O'Connor’s Aclaris Therapeutics ACRS Stock Holding History

UBS O'Connor’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-68,014
Closed -$466K – 507
2023
Q3 		$466K Sell
68,014
-5,000
-7% -$42.7K 0.01% 409
2023
Q2 		$757K Sell
73,014
-10,664
-13% -$96.5K 0.02% 409
2023
Q1 		$677K Sell
83,678
-51,015
-38% -$647K 0.02% 442
2022
Q4 		$2.12M Buy
134,693
+21,267
+19% +$342K 0.04% 455
2022
Q3 		$1.78M Hold
113,426
– – 0.02% 657
2022
Q2 		$1.58M Buy
113,426
+59,924
+112% +$840K 0.02% 700
2022
Q1 		$922K Buy
+53,502
New +$730K 0.01% 708

Other funds holding ACRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

UBS O'Connor's ACRS Position: Q4 2023 in Review

UBS O'Connor sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 68,014 shares — an estimated $466K sold.

UBS O'Connor first reported a position in ACRS in Q1 2022 and held it in 7 quarters. The position peaked at $2.12M in Q4 2022. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • UBS O'Connor reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 68,014 Aclaris Therapeutics shares in Q4 2023, an estimated $466K.
  • UBS O'Connor first reported a position in Aclaris Therapeutics in Q1 2022 and held it in 7 quarters.
  • UBS O'Connor's Aclaris Therapeutics position peaked at $2.12M in Q4 2022.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.